2025-522966-61-00
Not yet recruiting
Phase 1
A clinical study to investigate the safety, tolerability and pharmacokinetic profile of single ascending concentrations of OPT101 in peritoneal dialysis patients.
OPTERION Health AG1 site in 1 country12 target enrollmentStarted: January 9, 2026Last updated:
Overview
- Phase
- Phase 1
- Status
- Not yet recruiting
- Sponsor
- OPTERION Health AG
- Enrollment
- 12
- Locations
- 1
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Maxim Voropaiev
Scientific
OPTERION Health AG
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1/2
Clinical study to evaluate the safety and tolerability of SPVN06 (novel gene therapy) in a subset of patients with rod cone dystrophy (RCD).2022-501250-12-01Sparingvision17
Recruiting
Phase 1
Clinical study to test the safety, tolerance and preliminary efficacy of oral ITF3756 administered alone or in combination with an anti-protein 4 agent associated with cytotoxic T lymphocytes in patients with advanced solid tumors.2022-501089-22-00Italfarmaco S.p.A.60
Completed
Phase 1
Study is designed to assess the safety and tolerability of ceralasertib at increasing doses in combination with other anti-cancer treatment in patients with advanced tumours2023-505006-41-00AstraZeneca AB100
Recruiting
Phase 1/2
A study to investigate the safety and clinical activity of belantamab for the treatment of multiple myeloma when used as monotherapy and in combination treatments.2022-501941-63-00Glaxosmithkline Research & Development Limited3
Active, not recruiting
Phase 1/2
A trial to determine the safety and tolerability of transplanted stem cellderived dopamine neurons to the brains of individuals with Parkinson's Disease.2024-511237-35-00Region Skane4